Arca
Skip to content
Tools
Tools

Wet macular degeneration

Drug research and approvals for wet macular degeneration: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 31 studies of wet macular degeneration are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 25 authorised medicines for it.

  • Recruiting worldwide: 31
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 25

Recruiting now

Newest posted first, of 31 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 7

Phase 3 1

  • BevacizumabVascular endothelial growth factor A inhibitor

Phase 2 8

Phase 1 or earlier 9

How its trials ended

260 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 63 whose ending is known, 54% met their primary endpoint, 0% missed it and 46% stopped early.

  • Completed, result not reported12046%
  • Ongoing5320%
  • Met its primary endpoint3413%
  • Status unknown249%
  • Stopped: other or unclear156%
  • Stopped: lack of efficacy52%
  • Stopped: sponsor or business decision52%
  • Stopped: safety21%
  • Stopped: enrollment or feasibility21%

Medicines authorised in the EU

Newest first; 15 of 25
Sep 18, 2026SusvimoRanibizumabRoche Registration GmbHEMA ↗
Jul 15, 2026VislyfaRanibizumab · biosimilarLupin Europe GmbHEMA ↗
Jun 19, 2026RexatiluxRanibizumab · biosimilarIntas Third Party Sales 2005 S.L.EMA ↗
Feb 10, 2026RanluspecRanibizumab · biosimilarLupin Europe GmbHEMA ↗
Sep 15, 2025EyluxviAflibercept · biosimilarBiolitec pharma Limited Zweigniederlassung JenaEMA ↗
Aug 18, 2025MynzepliAflibercept · biosimilarAdvanz Pharma LimitedEMA ↗
Aug 18, 2025AfivegAflibercept · biosimilarSTADA Arzneimittel AGEMA ↗
Aug 14, 2025VgenfliAflibercept · biosimilarZaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.EMA ↗
Aug 14, 2025EiyzeyAflibercept · biosimilarZaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.EMA ↗
Feb 12, 2025EydenzeltAflibercept · biosimilarCelltrion Healthcare Hungary Kft.EMA ↗
Jan 13, 2025AhzantiveAflibercept · biosimilarFormycon AGEMA ↗
Jan 13, 2025BaiamaAflibercept · biosimilarFormycon AGEMA ↗
Nov 13, 2024AfqlirAflibercept · biosimilarSandoz GmbHEMA ↗
Nov 13, 2024OpuvizAflibercept · biosimilarSamsung Bioepis NL B.V.EMA ↗
Sep 19, 2024Epruvy (previously Ranibizumab Midas)Ranibizumab · biosimilarMidas Pharma GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.